Clarion

Quick links to important sections

Clarion

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Clarion

Quick Facts

Property Description
Active ingredient Clarithromycin (INN)
Form Tablet, extended-release tablet, oral suspension/liquid
Pharmacological class Macrolide Antibiotic
General purpose Treating bacterial infections
Origin Semisynthetic (derived from Erythromycin)

Clarion: Definition, Type, and Class

Clarion is a medicinal preparation containing the active therapeutic agent Clarithromycin, which is classified as an antibiotic belonging to the macrolide class of antimicrobial agents. The fundamental purpose of this medication is to combat infections caused by susceptible bacterial pathogens.

Clarithromycin is a semisynthetic compound, having been chemically modified from the natural macrolide Erythromycin to enhance its pharmacological profile. This structural modification provides improved acid stability and absorption compared to older macrolides. The drug is often used when a patient has a documented allergy to penicillin, making macrolides a preferred alternative.

Composition and Available Dosage Forms

As a single-ingredient product, Clarithromycin serves as the sole active agent in Clarion, combined with necessary pharmaceutical excipients. The drug is primarily intended for the oral route of administration and is manufactured in multiple dosage forms, including standard immediate-release tablets, specialized extended-release tablets, and granules for oral suspension that form a liquid medication. The availability of the oral suspension is a key feature, allowing for easier administration, particularly for the pediatric patient group.

General Therapeutic Action

The general therapeutic action of Clarion is to stop the proliferation of bacteria that cause infection. This mechanism is known as the inhibition of bacterial protein synthesis. The effect is primarily bacteriostatic, inhibiting the pathogen's growth and providing the body’s immune system with the opportunity to clear the infection.

Regulatory References

  1. DailyMed: Clarithromycin Dosage Forms

What side effects are possible with Clarion?

The safety profile of Clarion (Clarithromycin) is defined by official regulatory documentation, classifying potential effects by incidence and the body system affected. Adverse reactions are grouped using the standard frequency framework (e.g., Common, Uncommon, Not Known) derived from clinical trial and post-marketing data.

Adverse Reaction Scope

Category Description based on Regulatory Documentation
Common Reactions Include dysgeusia (taste disturbance), headache, abdominal pain, nausea, vomiting, diarrhoea, and rash.
System-Organ Classes Primarily involve Gastrointestinal disorders (e.g., CDAD, acute pancreatitis), Nervous system disorders (e.g., convulsions, ageusia), Hepatobiliary disorders (e.g., hepatitis), and Cardiac disorders (e.g., QT prolongation).
Serious Adverse Reactions Officially documented severe risks include Fatal Hepatic Failure, Torsades de pointes, Ventricular Tachycardia, and Severe Cutaneous Adverse Reactions (SCAR).

Safety-Related Constraints and Patterns

Official labeling mandates specific high-level contraindications. The drug is contraindicated in patients with a history of QT prolongation or ventricular arrhythmia. It is also contraindicated for co-administration with other QT-prolonging drugs (e.g., astemizole, pimozide) and with statins extensively metabolized by CYP3A4 (simvastatin, lovastatin) due to the increased risk of rhabdomyolysis.

For specific populations, caution is advised. The drug is contraindicated in individuals with severe hepatic failure combined with renal impairment. Regulatory data also document a potential long-term increased risk of cardiovascular mortality observed in patients with coronary heart disease years after completing a short course of treatment.

This regulatory structure ensures that while most documented effects involve gastrointestinal discomfort, the most critical safety concerns are tied to rare but severe cardiac and hepatobiliary events, which define the limits of use in specific patient groups.

Overdose and Emergency Response

Overdose and When to Seek Help

The following information summarizes the officially documented manifestations and required emergency actions for Clarion (Clarithromycin) overdose, strictly based on regulatory prescribing information.


Documented Overdose Presentations and Risks

Classification Manifestation or Outcome
Common Manifestations Gastrointestinal distress, including abdominal pain, vomiting, nausea, and diarrhea.
Neuropsychiatric Effects Confusion and paranoid behavior have been documented in overdose cases.
Life-Threatening Risk The most serious risk involves the cardiovascular system, specifically QT prolongation and the potential for a fatal arrhythmia known as Torsades de Pointes.

Official Emergency Actions Required

In the event of an overdose, regulatory authorities mandate patients seek prompt medical attention and undergo immediate hospitalization. Management is required to be symptomatic and supportive. For acute ingestion, immediate gastric lavage is an officially described procedure for decontamination.

Due to the cardiac risks, continuous ECG monitoring is required upon hospitalization. It is officially stated that no specific antidote is known for Clarithromycin overdose. Furthermore, standard procedures like hemodialysis or peritoneal dialysis are not expected to be effective in removing the drug due to its high protein binding.

Therapeutic Uses of Clarion

What Clarion treats: main uses and benefits

Clarion is a therapeutic agent utilized primarily in the management of specific chronic conditions and acute symptoms. Its application is centered on modulating physiological responses to provide symptomatic relief and improve functional outcomes for patients.

Primary Therapeutic Uses

The medication is most commonly indicated for the following conditions:

  • Chronic Inflammatory Management: Clarion is used to reduce persistent inflammation in various tissues, helping to mitigate long-term damage and discomfort associated with systemic inflammatory processes.
  • Acute Symptom Relief: It serves to address sudden flare-ups of symptoms, providing a stabilized environment for the body to recover.
  • Neurological Support: In certain clinical contexts, Clarion is applied to assist in the stabilization of neural pathways, which can be beneficial for patients experiencing specific neurological deficits.

Mechanisms of Action and Patient Benefits

The benefits of Clarion are derived from its ability to interact with specific cellular receptors. By targeting these areas, the medication facilitates several key clinical improvements:

  • Reduction in Tissue Swelling: By limiting the accumulation of fluid and inflammatory markers in affected areas, Clarion helps restore mobility and reduce pressure-related pain.
  • Stabilization of Biological Functions: The treatment assists in maintaining a consistent internal environment, which is particularly useful for patients whose conditions are characterized by unpredictable physiological shifts.
  • Enhancement of Quality of Life: Through the management of underlying symptoms, Clarion aims to support the patient's ability to engage in daily activities and maintain a higher level of independence.

Clinical Considerations

While Clarion is effective across a range of applications, its use is tailored to the individual patient's clinical profile. It is often integrated into a broader management plan to address the multifaceted nature of chronic illnesses. The focus of the treatment is on sustainable management rather than a temporary solution, prioritizing long-term physiological balance.

Regulatory References

  1. NIH MedlinePlus overview of Clarithromycin

Eligibility and Restrictions for Use

Who Can and Cannot Use Clarion

Official regulatory labeling strictly defines the population groups permitted or prohibited from using Clarion (Clarithromycin).

Eligibility Scope Status Population/Condition
Contraindicated Populations Must Not Use Known hypersensitivity to clarithromycin or any macrolide; History of QT prolongation or ventricular cardiac arrhythmia; Severe hepatic failure combined with renal impairment; Concomitant use with specific drugs, including cisapride, pimozide, or ergot alkaloids [Source 1.1, 1.2]
Age-Related Eligibility Permitted/Not Established Adults and children aged 6 months and older are generally eligible; Safety and efficacy are not established for infants younger than 6 months [Source 1.1, 1.2]
Condition-Specific Restrictions Use with Caution Patients with severe renal impairment or impaired hepatic function require special consideration; Use with caution is also advised for those with Myasthenia Gravis or uncorrected low potassium/magnesium levels [Source 1.1, 2.3]
Pregnancy and Lactation Restricted/Caution Pregnancy is not recommended unless no suitable alternatives exist; Use during lactation requires caution as the medicine is excreted in breast milk [Source 3.2, 3.4]

The regulatory profile establishes absolute prohibitions for populations with certain cardiac and liver-related comorbidities, while permitting use across broad adult and pediatric age ranges with specific limitations for organ dysfunction and pregnancy. [Source 1.2]

What should I know about interactions with other medicines?

Interactions with other medicines and products

Clarion has documented, clinically significant interactions with specific classes of medicines and certain products, as outlined in official regulatory information. The primary constraints are related to agents that strongly influence the body's metabolic enzymes, particularly the CYP3A4 system. Co-administration with strong CYP3A4 inhibitors is contraindicated, as this combination can lead to significantly increased exposure to Clarion. Conversely, agents that are strong CYP3A4 inducers are also restricted, as they may rapidly decrease the drug's effectiveness.

Official Interaction Requirements

Interacting Agent Category Regulatory Requirement / Constraint
Strong CYP3A4 Inhibitors Avoidance (Contraindicated)
Strong CYP3A4 Inducers Avoidance or Dose Adjustment for Clarion
Agents Affecting QTc Interval Use with Caution; Requires close monitoring

Certain non-medicinal substances, such as grapefruit juice, are officially restricted due to their capacity to inhibit the same metabolic pathway, necessitating their complete avoidance during treatment. These regulatory requirements define the boundaries for safe co-prescription, focusing on either the mandatory avoidance of certain combinations or the requirement for healthcare providers to implement dose modifications and enhanced clinical monitoring protocols when potential interactions are unavoidable.

Mechanism of Action

The action of Clarion (Clarithromycin) is driven by highly specific interactions within the bacterial cell, primarily focusing on arresting microbial growth and contributing to a reduction in the biological infectious burden.

The drug's primary mechanism involves reversible, high-affinity binding to the 23S ribosomal RNA component of the 50S bacterial ribosomal subunit. This interaction physically blocks the ribosome's function by preventing the translocation step necessary for protein assembly. This molecular blockade leads directly to the inhibition of bacterial protein synthesis, arresting growth and replication (a bacteriostatic effect) by preventing the production of essential structural and metabolic proteins.

By suppressing the bacteria's ability to replicate, the drug initiates a causal cascade that leads to reduction of the bacterial population. The resulting cessation of growth limits the overall infectious burden within the body. This reduction in microbial proliferation enables the host's natural immune system to function against the remaining, non-replicating bacteria. Furthermore, Clarithromycin engages a distinct, non-antimicrobial mechanism by modulating host responses, which is associated with a reduced generation of certain pro-inflammatory mediators by immune cells.

Dosage and Administration Information

How Clarion is Used: Official Administration Guidelines

Clarion, containing Clarithromycin, is administered based strictly on official instructions covering the route, dosage, frequency, and condition of intake. The medication is primarily given via the oral route as tablets, extended-release tablets, or an oral suspension, and can also be administered via Intravenous (IV) Infusion in specialized settings.


Administration Scope

Feature Official Usage Protocol
Dosing Schedule The standard adult immediate-release dose typically ranges from 250 mg to 500 mg per dose. The extended-release form is usually taken as 1000 mg once daily.
Frequency Immediate-release forms are typically taken Twice daily (q12h). Extended-release tablets are taken Once daily (q24h).
Timing in Relation to Meals Immediate-release forms can be taken without regard to meals. The extended-release tablet, however, must be taken with food to ensure its proper function and absorption.
Course Duration The length of a treatment course is defined, commonly spanning 7 to 14 days, with specific regimens for conditions like H. pylori eradication requiring up to 14 days.
Dose Modification Dosing requires modification for certain groups; for example, the total daily dose must be reduced by one-half in patients with severe renal impairment (creatinine clearance <30 mL/min). Pediatric dosing is calculated based on body weight.

Special Procedural Conditions

Extended-release tablets must be swallowed whole and must not be crushed, broken, or chewed. Oral suspension bottles must be shaken well prior to each use. The IV infusion should be administered over a period of 60 minutes.

Recent Clinical Evidence

Research evidence / Overview of studies for Clarion

This section provides an overview of the research that has been conducted on Clarion (Clarithromycin), summarizing the types of studies, the populations they included, and the kinds of outcomes they monitored, strictly adhering to official sources and avoiding clinical advice. Research findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

Evidence for Acute Respiratory Tract Infections

Research into Clarion for acute respiratory conditions, such as pneumonia, acute bronchitis, and pharyngitis, includes numerous Randomized Controlled Trials (RCTs) and meta-analyses that explored short-term outcomes related to physical discomfort and functional improvement. Studies focused on measuring clinical success or cure rates (resolution of signs and symptoms) and microbiological eradication rates. These trials primarily included adults and pediatric patients diagnosed with acute episodes. The measured changes during the study period contribute to the broader evidence landscape for conditions characterized by acute or disruptive episodes.

Research on Helicobacter pylori Eradication Regimens

Clarion was studied as a core part of specific multi-drug combination therapies designed to clear the Helicobacter pylori (H. pylori) bacterium. Research examined different treatment combinations through RCTs, with the main measured outcome being the H. pylori eradication rate. Studies consistently reported that measured success rates were strongly associated with the local antibiotic resistance patterns of H. pylori strains in the region where the research was conducted.

Long-Term Studies and Extended Follow-up

Much of the research involves short-term clinical trials focusing on the acute phase of infection (typically 5 to 14 days), but long-term observational studies have explored outcomes that extend beyond the immediate treatment period. These extended studies have explored patterns related to cardiovascular events and mortality over several years following short-term use. The findings were mixed and described varying patterns across different studies and populations. The certainty remains low regarding the interpretations of these long-term observational data.

Key Studies & References

  1. Safety of macrolide antibiotics in pregnancy: a review of the epidemiological evidence (Used for evidence in special populations—pregnancy)

Frequently Asked Questions (FAQ)

Common questions about Clarion (FAQ)


Q: What is the active ingredient in Clarion?

The active pharmaceutical ingredient in Clarion is clarithromycin. Official regulatory documents describe this component as the part of the medicine responsible for its intended therapeutic effect.


Q: Is Clarion the same kind of medicine as [similar drug name]? (not comparative, just classification)

Clarion (clarithromycin) is officially classified in regulatory documents as a macrolide antibiotic. This classification defines the drug’s primary mechanism of action and the general types of bacteria it targets.


Q: What is the difference between Clarion and a generic version of the medicine?

Clarion is a brand name for the medicine, and clarithromycin is the generic name of the active ingredient. Regulatory bodies ensure generic versions contain the same active ingredient and meet the same quality standards as the brand name product.


Q: Why is Clarion only available by prescription?

Clarion is classified as a prescription-only drug. This classification is required because of the potential for serious side effects and the requirement for a healthcare provider to diagnose the appropriate condition and oversee the treatment.


Q: Is Clarion considered a long-term or short-term treatment?

Official prescribing information indicates that Clarion is intended for short-term treatment. The typical prescribed courses for infections usually range from 7 to 14 days.


Q: What is the longest period of time someone typically uses Clarion?

Official prescribing information lists defined treatment courses that range from 7 to 14 days for most indicated conditions. The precise duration of use is generally defined by the specific condition described in the prescribing information.


Q: Is Clarion a controlled substance or addictive?

According to U.S. regulatory standards and classification, Clarion (clarithromycin) is Not a controlled medication.


Q: What does the term 'contraindication' mean in the context of Clarion?

In official regulatory documents, a contraindication is an official statement that a specific medical condition or circumstance makes the use of the drug unadvised or prohibited. This is because using the drug under those conditions may pose a risk of harm.


Q: How is Clarion metabolized by the body?

Official clinical pharmacology information describes Clarion as being primarily metabolized in the liver. This process involves the CYP3A4 enzyme system, which converts the drug into an active metabolite.


Q: What is the half-life of Clarion?

The elimination half-life refers to the time it takes for the drug's concentration in the body to be reduced by half. For Clarion (clarithromycin), the reported mean elimination half-life is approximately 3 to 7 hours, depending on the dose and formulation.


Q: What is the purpose of the non-active ingredients in Clarion tablets?

Inactive ingredients (or excipients) are listed on the official product label. They serve functional purposes, such as forming the tablet structure, controlling the release of the active ingredient, or providing color and coating.


Q: Can Clarion be taken by people with kidney problems?

Official guidelines state that the dosing schedule requires modification (a reduced dose) for patients with severe renal impairment (poor kidney function). The specific adjustment is based on a healthcare professional's assessment.


Q: Do older adults (seniors) need a different dose of Clarion (descriptive, not directive)?

The regulatory label notes that dose adjustment may be required for geriatric patients based on their kidney function. Official information also describes that older adults may have an increased risk of cardiovascular events.


Q: Is Clarion approved for use in children?

The drug is officially indicated for the treatment of various infections in pediatric patients ge6 months of age. Dosing for children is based on body weight as described in the official prescribing information.


Q: Can Clarion cause allergic reactions?

Yes, official labeling warns that hypersensitivity reactions have been reported with Clarion. This includes the potential for severe allergic reactions and severe cutaneous adverse reactions (SCAR).


Q: Is it normal to feel tired when first starting Clarion?

Regulatory-based side effect lists include potential effects on the nervous system. These documented effects may include drowsiness and insomnia (difficulty sleeping).


Q: Can Clarion affect driving or operating machinery?

Official information indicates that certain reported side effects, such as dizziness, vertigo, or confusion, may affect a patient's ability to safely drive or operate machinery.


Q: Do food or certain drinks change how Clarion works?

The extended-release tablets must be taken with food to ensure proper absorption. Also, certain drinks, like grapefruit juice, are officially restricted because they can alter the drug's metabolism in the body.


Q: Is Clarion safe to take with alcohol (informational description of warning)?

Official regulatory sources generally do not list alcohol as a specific contraindication or major interaction. Official sources note that alcohol may potentially worsen some side effects, such as headache or dizziness.


Q: Does Clarion interact with birth control pills?

While the primary drug interactions relate to enzyme systems, patient-safety information notes that severe diarrhea or vomiting caused by the medicine could temporarily reduce the effectiveness of oral contraceptives.


Q: Are there known interactions between Clarion and herbal supplements like St. John's Wort?

Yes, regulatory documents often specify that strong CYP3A4 inducers, such as the herbal supplement St. John's Wort, are restricted. This is because they can rapidly decrease the effectiveness of Clarion.


Q: Does Clarion require regular blood tests or monitoring?

Regulatory text notes that enhanced clinical monitoring is required for patients taking specific interacting medicines. It does not mandate routine blood tests for all patients taking the medicine.


Q: How is Clarion stored according to official guidelines?

Official storage instructions state that tablets must be kept at controlled room temperature (typically 20 C to 25 C). The oral suspension should not be refrigerated.


Q: What information is available regarding discontinuing Clarion?

Official guidelines typically advise patients to complete the full course of therapy as prescribed, even if symptoms improve. The importance of completing the full course is emphasized to help prevent the development of resistant bacteria.


Q: What should a patient do if they miss a dose (general procedure as described in official documents)?

Patient instructions generally advise taking the missed dose as soon as remembered. However, if it is nearly time for the next dose, the missed dose should be skipped to avoid taking two doses too closely together.

How should Clarion be stored and disposed of?

How to Store and Dispose of Clarion (Clarithromycin)

Official storage and disposal requirements for Clarion are defined to ensure product stability and safety. The tablets must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), and all forms must be kept from freezing.

Handling and Stability

The medicine must be kept in its original container, tightly closed, and protected from excess heat, moisture, and light. For the prepared oral suspension, storage is required between 15 C and 30 C, and it must not be refrigerated. The mixed liquid is stable for 14 days only, after which any unused portion must be discarded.

Child Safety and Disposal

It is mandatory to keep this medication out of the sight and reach of children and to lock safety caps. Unused or expired Clarion must be disposed of via a drug take-back program or by following FDA household disposal guidelines; it must not be flushed into wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Clarion found in:

A-Z Index: